Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$50 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$2.9
EPS
$-2
Face value
--
Shares outstanding
38,744,446
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acrivon Therapeutics, Inc. (ACRV)
| -36.9 | 0.7 | -36.9 | -9.5 | -50.7 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Acrivon Therapeutics, Inc. (ACRV)
| -60.0 | 22.2 | -57.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acrivon Therapeutics, Inc. (ACRV)
|
1.5 | 50.0 | 0.0 | -77.9 | -- | -53.9 | -- | 0.4 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics... platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472 Read more
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Dr. Peter Blume-Jensen M.D., Ph.D.
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Dr. Peter Blume-Jensen M.D., Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Acrivon Therapeutics, Inc (ACRV) is $1.52 (NASDAQ) as of 02-Apr-2026 18:37 EDT. Acrivon Therapeutics, Inc (ACRV) has given a return of -50.71% in the last 3 years.
Since, TTM earnings of Acrivon Therapeutics, Inc (ACRV) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.21
|
0.84
|
|
2024
|
-2.54
|
1.16
|
|
2023
|
-1.79
|
0.89
|
|
2022
|
-1.55
|
0.27
|
|
2021
|
--
|
--
|
The 52-week high and low of Acrivon Therapeutics, Inc (ACRV) are Rs 3.56 and Rs 1.05 as of 04-Apr-2026.
Acrivon Therapeutics, Inc (ACRV) has a market capitalisation of $ 50 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Acrivon Therapeutics, Inc (ACRV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.